Autonomize AI

The agents are the product. There is no system of record, no services organisation and no legacy platform beneath them, and the company positions explicitly against general purpose models retrofitted for healthcare, claiming healthcare specific understanding of medical context, terminology and operational nuance as the differentiator. Every commercial line, prior authorisation, payment integrity, care gaps, chart review, case management, is an agent built on the same orchestration layer.

Human oversight is stated as a design differentiator rather than assumed. The chief executive describes a human in the loop approach in which clinical teams retain full control while agents remove administrative work, and the platform names real time governance and explainability as capabilities. That framing is deliberate and better than the norm on the payer side. Held at B because none of it is specified anywhere a buyer can check. No confidence threshold, no routing rule, no abstention behaviour, no error rate and no statement of which determinations require human sign off was located. One structural point matters more here than the missing parameters: with more than 160 agents, an oversight claim made at platform level says nothing about how any individual agent behaves, and the risk profile of a care gap summary and a coverage determination are not remotely the same. Ask for the oversight model agent by agent, starting with any agent that touches an adverse determination.

Explainability and real time governance are named as platform capabilities, which is more than most payer side vendors claim, but neither is described in any detail that a buyer could evaluate. No model or model family is named, no accuracy figure is published for any agent, no evaluation methodology or error taxonomy exists, and there is no model card. The published numbers are uniformly efficiency measures rather than correctness measures. One claim sits closest to accuracy, an 80 percent reduction in manual errors, and it carries no baseline, no definition of what counts as an error and no measurement method, so it cannot be read as evidence about output quality.

Substantial commercial traction with no published measure of correctness, which this index grades C. A 28 million dollar Series A, deployments described at Fortune 100 healthcare organisations and top 20 pharmaceutical companies, distribution through the Microsoft marketplaces, and a named executive endorsement from Lyric, itself an indexed vendor in this category, are all real signals about adoption. None of them is an organisation named as a customer, and none is a study. Every reported outcome is an efficiency figure, 78 percent less time per case, 85 percent better case review efficiency, up to 55 percent staff time savings, prior authorisation collapsing from twenty or thirty minutes to seconds, and all are vendor reported without a stated baseline, denominator or method. Nothing published establishes whether the agents reach the right conclusions.

No retention period, no statement on whether customer data is used to train or improve agents, and no de identification posture was located. A HIPAA and SOC 2 compliance posture is claimed but that is a compliance statement rather than a stewardship one. Not Rated records absent evidence. The scope makes the questions material: the platform ingests clinical notes, faxes, PDFs and claims across health plans, provider organisations and life sciences customers simultaneously, so establish what separation exists between customer estates and whether anything learned from one informs another.

HIPAA compliance is claimed alongside SOC 2, with no business associate agreement terms published, which is the standard middle rung. Worth establishing separately for the life sciences line, since research and clinical trial work may run under different authorisations and agreements than the payer and provider work, and a single platform level compliance statement will not describe both.

SOC 2 is claimed for the company itself, which is the right subject, but the report type is not specified on any retrieved surface and Type I versus Type II is the whole assurance question. No trust centre, security page, status page or scope statement was located. One point in its favour that stops short of changing the grade: the products are listed in the Microsoft marketplaces, and a platform vendor applies its own technical review before listing, which is a modest external signal of the kind this index credited for marketplace distribution elsewhere. Ask which SOC 2 report exists, over what period, and request it directly.

No FDA clearance or device authorisation was located and none is expected, since the agents inform coverage, payment and administrative determinations rather than diagnosis or treatment. The regulatory exposure sits squarely in payer regulation and it is moving quickly: CMS interoperability and prior authorisation requirements that took effect in 2026 mandating electronic submission and faster turnaround, and a growing set of state laws restricting or conditioning AI involvement in coverage denials. A plan buying agentic prior authorisation inherits that exposure, and it is not something a pricing negotiation surfaces.

The grade describes disclosure, and the credit is genuine. Naming real time governance as a platform capability rather than as a policy, alongside explainability and an explicit human in the loop stance, is more than most payer side vendors offer. Three things hold it at C. First and most important, this index holds that on the payer side automating an approval is low risk while automating a denial is not, and nothing published states whether any agent can influence, prepare or generate an adverse determination, or what human review is mandatory on that path. The payment integrity line, which embeds review before improper claims are paid, sits on the same side of that question. Second, a governance claim made at platform level across more than 160 agents does not describe the behaviour of any one of them, and the risk sits at agent level. Third, no fairness, subgroup or demographic performance disclosure of any kind was located, which matters in prior authorisation and care gap work where differential outcomes are well documented.

Interoperability here means plan systems rather than EHRs, and the stated position is sensible but unnamed. The company says its copilots interface with a health plan's existing internal and third party prior authorisation and medical policy systems without requiring changes to the medical management platform, which is the right architectural promise for that buyer and lowers adoption friction. Ingestion is format agnostic across clinical notes, PDFs, faxes and claims. Graded C because no medical management, utilisation management or EHR system is named anywhere, no integration standard is described, and the only concrete distribution surface located is the Microsoft marketplaces. Ask which specific platforms are in production today rather than which are theoretically supported.

Described as integrating with major cloud providers and distributed through the Microsoft marketplaces, which establishes cloud delivery. No region, residency commitment or explicit customer hosted option was located. One question is worth asking directly because the answer would materially change the data posture: whether marketplace availability means the platform can be deployed into the customer's own cloud tenancy, where clinical content would remain inside infrastructure the plan controls, or whether it is vendor hosted with the marketplace serving only as a procurement route. Those are very different postures and the public material does not distinguish them.

No price, tier or pricing mechanism was located on any retrieved surface. Not Rated is the house convention for absent pricing rather than a low grade. Worth checking the Microsoft marketplace listings directly during evaluation, since marketplace distribution sometimes carries published or transactable pricing that a vendor's own site does not, and if it does that would be a materially more transparent route than the standard enterprise negotiation.

Broad across buyer types and workflows rather than deep in a clinical specialty. Three distinct markets are served, health plans, provider organisations and life sciences companies, and the workflow coverage spans prior authorisation, payment integrity and pre payment review, benefit determination between medical and pharmacy, HEDIS care gap analysis, case management, chart review and clinical trial planning. Within prior authorisation the company names specific service categories including inpatient, imaging, cardiology and durable medical equipment, which is more granularity than most competitors offer on that axis. Graded B rather than A because the breadth comes from many prebuilt agents on one orchestration layer rather than from instrument level depth in any single workflow.